Dr Méd. Pascal Mock
FM.H Specialist in Gynecology and Obstetrics
Advanced training in reproductive medicine and gynecological endocrinology
Pascal MOCK, MD, MSc, studied the medicine at the medical school of the University of Geneva (Switzerland). After having practiced as obstetrician and gynecologist at the University Hospital of Geneva (HUG), he further continued a specialization in Reproductive Medicine in Paris (France) at the Antoine- Béclère Hospital concluding with a Master in Physiology of Reproduction at the Pierre et Marie Curie University (Paris VI, 1998). Back to Switzerland, he obtained the certification as specialist FMH in Reproductive Medicine in 2001. Dr Mock’s research area is human embryo implantation. Between 1999 and 2001 he was the Director of a Swiss national fund for scientific research, working on the biological activity of a new placental molecule of the insulin family (INSL4). He authored several high levels scientific publications about infertility and embryo implantation. He gave lectures at the University of Geneva.
In 2004 with the business angel Martin Velasco he founded, ANECOVA, a biotech swiss company, in order to develop his invention, a novel in vivo culture system in the field of assisted reproductive technology. His collaboration with the EPFL was important during this creative period. In 2009 he obtained the first baby in the world born after in vivo fertilization using this new system at the clinic des Grangettes in Geneva.
El-Minawi AM, Campana A, Mock P.
Difficult IVF embryo transfer : Are ovarian steroids implicated ? A Hypothesis (submission to Fertility and Sterility on November 2001)
Mock P, Meisser A, Wuillemin C, Araman M, Campana A, Bischof P. (2000)
Secretion of human chorionic gonadotrophin (hCG) and gelatinase A (MMP-2) by trophoblastic cells : Up- and down-regulation by relaxin (RLX). Manuscript published in the Proceedings of RELAXIN 2000-3rd International Conference on Relaxin and Related Peptides in March 2001
Mock P. (1998)
Etude de l’expression de early placenta insulin-like (EPIL), produit du gène INSL4, au niveau du placenta et de l’utérus. Mémoire de Diplôme d’Etudes Approfondies de Physiologie de la Reproduction, Responsable scientifique : Professeur Jean-Michel Bidart, Université Paris VI, Pierre et Marie Curie, Paris
Mock, P. (1998)
Are women requiring unplanned intrapartum epidural analgesia different in a low-obstetrical risk population? Thèse de Doctorat en Médecine, Université de Lausanne, Directeur de Thèse : Professeur Fred Paccaud
- C. Blockeel, P. Mock, G. Verheyen, N. Bouche, Ph. Le Goff, Y. Heyman, C. Wrenzycki, K. Höffmann, H. Niemann, P. Haentjens, M.J. de Los Santos, M. Fernandez-Sanchez, M. Velasco, P. Aebischer, P. Devroey, and C. Simon (2009)
- An in vivo culture system for human embryos using an encapsulation technology: a pilot study Hum.Reprod 2009;24:790–796.
- Islami D, Mock P and Bischof P
Effects of human chorionic gonadotrophin on trophoblast (2001) Seminars in Reproductive Medecine 19, 49-53
- Mock P, Olivennes F, Doumerc S, Frydman R and Fernandez H.
Simultaneous bilateral tubal pregnancy after intracytoplasmic sperm injection treated by conservative medical treatment : Interest of sonographic follow-up. (2001) Eur. J Obstet. Gynecol. Reprod. Biol., 94, 155-157.
- Mock P, Frydman R, Bellet D, Chassin D, Bischof P, Campana A, Bidart JM. (2000)
Expression of pro-EPIL peptides, encoded by the insulin-like4 (INSL4) gene, in chromosomally abnormal pregnancies. J. Cl. Endocrinol. Metab., 85, 3941-3944.
- Mock P, Kovalevskaya G, O’Connor D, Campana A. (2000)
Choriocarcinoma-like hCG and human chorionic gonadotropin bioactivity during the first trimester of pregnancy. Hum. Reprod., 15, 2209-2214.
- Mock P, Frydman R, Bellet D, Diawara DA, Lavaissiere L, Troalen F, Bidart JM. (1999)
Pro-EPIL forms are present in amniotic fluid and maternal serum during normal pregnancy. J. Cl. Endocrinol. Metab., 84, 2253-2254.
- Mock P, Santos-Eggimann B, Bérod ACl, Ditesheim PJ, Paccaud F. (1999)
Are women requiring unplanned intrapartum epidural analgesia different in a low-obstetrical risk population? International J. Obst. Anaest., 8, 94-100.
- Mock P, Bischof P, Rivest R, Campana A, Chardonnens D. (1998)
Modulation of human chorionic gonodotrophin bioactivity during the first trimester of pregnancy. Hum. Reprod., 13, 2629-2632.
- Mock P, Chardonnens D, Stamm P, Bischof P, Campana A. (1998)
The apparent late half-life of human chorionic gonadotropin (hCG) after surgical treatment for ectopic pregnancy. A new approach to diagnose persistent trophoblastic activity. Eur. J Obstet. Gynecol. Reprod. Biol., 78, 99-102.
- Bellet D, Lavaissière L, Mock P, Laurent A, Sabourin JC, Bedossa P, Le bouteiller P, Frydman R, Troalen F, Bidart JM (1997)
Identification of pro-EPIL and EPIL peptides translated from Insulin-like 4 (INSL4) mRNA in human placenta. J. Clin. Endocrinol. Metab., 82, 3169-3172.
|June 2010||300 personnalités
les plus influentes de Suisse
|Bilan nr. 13 30th June 2010
Extract pages 86-87 PDF
|March 2010||Les Fruits de l’Excellence
“Plus de nature in vivo” contribution p.16-17 see PDF
|Université de Genève
Plaquette 25 pages PDF
|December 2009||« Scientific father » of the 1st baby in the world born after an in vivo assisted fecondation without use of incubator||Press release Anecova
Le Temps 15 dec. 2009
|January 2008||Anecova named pioneering technology company||World Economic Forum Davos|
|March 2004||Anecova Company Foundation||With Martin VELASCO|
|July 2002||Invention new concept of fertilization IN Vivo assisted||Dépôt de brevet EP 1639 972 A1|
|May 1999||Diplôme de Spécialiste FMH en Gynécologie et Obstétrique||Swiss Society of Medicine FMH|
|October 1998||Doctoral thesis in medicine||University of Lausanne|
|September 1998||Diploma of Advanced Studies in Reproductive Physiology||Pierre and Marie Curie University, Paris VI|
|July 1997||British Fertility Society Prize||Annual conference, Fertility Societies, University of York, 16-18 jul 1997|
|March 1990||Federal Diploma of Medecin||University of Geneva|
El-Minawi AM, Campana A, Mock P.
Difficult IVF embryo transfer : Are ovarian steroids implicated ? A Hypothesis Presentation at the 12th World Congress on in vitro fertilization and molecular reproduction in March 16-19 2001, Buenos Aires, Argentina
Urner F, Lucas H, Sakkas D, Chardonnens D, Bianchi G, Mock P, Campana A, Leppens-Luisier G.
Localization of tyrosine phosphorylated proteins in human sperm and relation to IVF success. Presentation at ESHRE 2001, Lausanne, Switzerland.
Mock P, Meisser A, Vuillemin C, Araman M, Campana A, Bischof P.
Secretion of human chorionic gonadotrophin (hCG) and gelatinase A (MMP-2) by trophoblastic cells : Up-regulation by relaxin (RLX). Presentation at the BAS/BFS/SSF Joint Fertility Societies Meeting, EICC, 31st July-2nd August, 2000, Edinburgh, UK
De Ziegler D, Brioschi PA, Howarth N, Mock P, Fanchin R, Bulletti C.
Mock intrauterine inseminations (IUI) to study end follicular phase uterine contractility. Presentation at the American Society for Reproductive Medicine, 56th Annual Meeting-October 21-25, 2000, San Diego, CA. Published in Fertility and Sterility
Leppens-Luisier, G., Lucas, H., Chardonnens, D., de Ziegler, D., Bianchi, P.G., Mock, P., Campana, A., Urner, F.
G1.2/G2.2 : Effect on mouse embryo development and preliminary results in human IVF. Presentation at the American Society for Reproductive Medicine, 56th Annual Meeting-October 21-25, 2000, San Diego, CA
Mock, P., Luedicke, F., Chardonnens, D., Bianchi, G., Bischof, P., De Ziegler, D. And Campana, A.
Homolateral uterine artery impedance is preferentially lowered by the corpus luteum suggesting direct effects of this organ on uterine blood flow through a local circulatory phenomenon. Oral presentation at the 11th World Congress on In Vitro Fertilization and Human Reproductive Genetics in Sydney on May 1999
Straccia, A.-T., Vlastos, G., Mock, P., Huang, J., Li, H.W., Campana, A., Morabia, A.
Breast cancer and risk factors : A comparative epidemiological study between a low and a high risk population. Poster session at the First European Breast Cancer Conference, Florence, 29th September-3rd October 1998
- Intrauterine device, method of making such a device and method for putting active elements within the uterine cavity
- Method for identifying and locating expressed EPIL peptides, coded by the INSL4 gene and their uses